DSGN (designtx.com) Earnings growth forecast for next year
Design Therapeutics is developing GeneTAC for gene regulation in neurodegeneration, which supports the forward-looking net earnings per share growth, where the -16.80 mark records this metric. Design Therapeutics is diversifying its portfolio with targeted treatments for genetic pathologies, leveraging a solid liquidity reserve and zero debt to successfully advance clinical trials.
Analytical breakdowns and data insights for company designtx.com (DSGN)
- stock quotes and analyst forecast:
- business market valuation indicators:
- book capitalization indicators:
- company total debt and liquidity indicators:
Total Debt to Capital Design Therapeutics|DSGN - Long-Term Debt to Capital|Short-Term Debt to Equity Design Therapeutics, Inc.|DSGN - Company Aggregate Indebtedness|Debts to Book Capitalization Design Therapeutics|DSGN - Long-Term Debt|Company Current Liabilities Design Therapeutics|Quick Liquidity Indicator designtx.com
- earnings and valuation multiples information:
DSGN - Profit After Payment of Taxes|Projected Future Earnings Design Therapeutics|DSGN - Business Payback Period|Forward P/E Multiple Design Therapeutics|DSGN - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Design Therapeutics|DSGN - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Design Therapeutics|DSGN - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months designtx.com|DSGN - Expected net earnings per share growth this year|Earnings growth forecast for next year Design Therapeutics
- total revenue and sales volume data:
Summary company analytics:Design Pharma, DSGN
Design Therapeutics develops advanced methods for correcting genetic mutations to restore protein synthesis. This calculation measures the expected earnings per share (EPS) dynamics by aggregating expert forecasts for future cash flows. An analysis of the consensus forecast for forward EPS growth rates allows for an assessment of market expectations regarding the commercialization of innovations. The stability of this indicator confirms the fundamental resilience of the asset within the biotechnology sector.
Competitors of Design Therapeutics
Expected earnings per share growth for next year TEM|QGEN (Qiagen Corp) - Projected earnings per share increase next year|Earnings growth forecast for next year IONS|RGEN (repligen.com) - Expected earnings per share trend next year|Earnings growth forecast for next year RNA (Avidity Biosciences, Inc.)|CRISPR Therapeutics Inc (CRSP) - Expected net earnings per share growth next year|WGS - Net earnings per share growth forecast for next year|Expected earnings per share trend next year RARE (Ultragenyx Corp)|BEAM: Earnings growth forecast for next year|sarepta.com (SRPT) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year Twist Bioscience, Inc.|10x Genomics Inc - Net earnings per share change forecast for next year|Earnings growth forecast for next year NTLA|STOK - Expected net earnings per share growth next year|BioLife Solutions, Inc. - Expected earnings per share growth for next year|Earnings growth forecast for next year wavelifesciences.com WVE|MAZE: Expected earnings per share growth for next year|Sionna Therapeutics, Inc. - Projected earnings per share increase next year|PRME: Earnings growth forecast for next year|TSHA - Consensus forecast of earnings per share growth for next year|QURE (uniQure N.V.) - Earnings growth forecast for next year|Expected earnings per share growth for next year meiragtx.com (MGTX)|Net earnings per share growth forecast for next year REGENXBIO (RGNX)|Consensus forecast of earnings per share growth for next year Solid Biosciences Inc|Earnings growth forecast for next year OCGN (Ocugen Corp)|PACB: Projected earnings per share growth rate for next year|BNTC - Net earnings per share growth forecast for next year|Consensus forecast of earnings per share growth for next year rocketpharma.com RCKT|FDMT: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Lexeo Therapeutics, Inc. LXEO|Net earnings per share growth forecast for next year Korro Bio Inc.|Projected earnings per share growth rate for next year EDIT (Editas Corp)|Earnings growth forecast for next year SLN|proqr.com - Projected earnings per share growth rate for next year|Net earnings per share growth forecast for next year Codexis CDXS|SGMO: Projected earnings per share growth rate for next year|Nautilus Biotechnology Inc - Earnings growth forecast for next year|MGX - Earnings growth forecast for next year|DTIL: Earnings growth forecast for next year|Projected earnings per share growth rate for next year GBIO|BOLD (Boundless Bio) - Earnings growth forecast for next year|Expected net earnings per share growth next year Exicure Corp XCUR|Net earnings per share growth forecast for next year Imunon, Inc. (IMNN)|Consensus forecast of earnings per share growth for next year phiopharma.com|Earnings growth forecast for next year MBIO (Mustang Bio)|Consensus forecast of earnings per share growth for next year TransCode Therapeutics Inc. (RNAZ)|Bionano - Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Applied DNA Sciences Inc (APDN)|Bluebird Bio (BLUE) - Net earnings per share growth forecast for next year|Projected earnings per share growth rate for next year IPA|Expected earnings per share growth for next year OMGA|OMIC: Expected earnings per share trend next year|Expected earnings per share growth for next year RGLS (Regulus Therapeutics Inc.)|Projected earnings per share increase next year SYRS|Earnings growth forecast for next year TBIO (Codex DNA)|Expected earnings per share trend next year TCON|Unity Biotechnology - Earnings growth forecast for next year
